These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 23648372)

  • 21. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
    N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabis for inflammatory bowel disease.
    Naftali T; Mechulam R; Lev LB; Konikoff FM
    Dig Dis; 2014; 32(4):468-74. PubMed ID: 24969296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
    Cosnes J; Bourrier A; Laharie D; Nahon S; Bouhnik Y; Carbonnel F; Allez M; Dupas JL; Reimund JM; Savoye G; Jouet P; Moreau J; Mary JY; Colombel JF;
    Gastroenterology; 2013 Oct; 145(4):758-65.e2; quiz e14-5. PubMed ID: 23644079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial.
    Krebs S; Omer TN; Omer B
    Phytomedicine; 2010 Apr; 17(5):305-9. PubMed ID: 19962291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
    Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
    Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Cohen A; Bitton A; Baker J; Dubé R; Landau SB; Vandervoort MK; Parikh A
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1370-7. PubMed ID: 18829392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome.
    Lahiff C; Safaie P; Awais A; Akbari M; Gashin L; Sheth S; Lembo A; Leffler D; Moss AC; Cheifetz AS
    Aliment Pharmacol Ther; 2013 Apr; 37(8):786-94. PubMed ID: 23432394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
    Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
    Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
    Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.